A Multi-Centre, Real-World Study on the Efficacy of PureDelivery® LAN (CatarClear®) for the Non-Surgical Management of Cataracts in Companion Animals in Singapore
DOI:
https://doi.org/10.47672/ejah.2764Keywords:
Catarclear®, Cataract, Companion Animals, Quality Of Life (Qol), Efficacy, Puredelivery® Lanosterol Nano-Formulation (Puredelivery® LAN)Abstract
Purpose: To evaluate the real-world efficacy and usability of PureDelivery® LAN (CatarClear®), a topical proprietary lanosterol (LAN) nano-formulation, for the non-surgical management of naturally occurring cataracts in companion animals.
Materials and Methods: About 100 dogs and a smaller cohort of other small animal pets (e.g., cats, rabbits) diagnosed with cataracts of varying stages and etiologies. A clinical data collection study was conducted over twelve months across multiple veterinary practices in Singapore. Over 10 participating veterinary surgeons treated animals with PureDelivery® LAN (CatarClear®), administered topically twice daily for a minimum of six weeks. Efficacy was assessed based on a predefined categorical scale that is significant improvement, slight improvement, no improvement, through ophthalmic examination. Data on ease of administration and overall recommendations were also collected.
Findings: Of the treated animals, 98% showed measurable improvement in cataract presentation following the treatment regimen. The improvement was categorized as significant in a notable portion of cases, particularly those with early-stage cataracts. The formulation was reported by veterinarians to be easily administered by pet owners. This study demonstrates that PureDelivery® LAN (CatarClear®) is a highly effective, non-invasive therapeutic option for managing cataracts in companion animals, especially in cases where ophthalmologic surgery is contra-indicated due to age, health risks, anaesthesia concerns, or financial constraints.
Unique Contribution to Theory, Practice and Policy: Future studies should be designed as randomized, controlled, and blinded trials. Incorporating objective measures like digital image analysis of lens opacity, electroretinography (ERG), and more detailed visual obstacle course testing would strengthen the findings (20, 21). Longitudinal studies are also warranted to assess the long-term efficacy, safety, and potential for cataract recurrence after cessation of treatment across a wider range of species.
Downloads
References
1. Cicinelli MV, Buchan JC, Nicholson M, Varadaraj V, Khanna RC. Cataracts. The Lancet. 2023;401(10374):377-89.
2. Heruye SH, Maffofou Nkenyi LN, Singh NU, Yalzadeh D, Ngele KK, Njie-Mbye Y-F, et al. Current trends in the pharmacotherapy of cataracts. Pharmaceuticals. 2020;13(1):15.
3. Pfahler S, Menzel J, Brahm R, Rosenhagen CU, Hafemeister B, Schmidt U, et al. Prevalence and formation of primary cataracts and persistent hyperplastic tunica vasculosa lentis in the German Pinscher population in Germany. Veterinary Ophthalmology. 2015;18(2):135-40.
4. Basher AW, Roberts SM. Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs. Veterinary Clinics: Small Animal Practice. 1995;25(3):661-76.
5. Davidson M, Nelms S. Diseases of the canine lens and cataract formation. Veterinary ophthalmology. 2007;2:859-87.
6. Wilkie DA, Colitz C. Surgery of the canine lens. Veterinary ophthalmology. 2007;2:888-931.
7. Brodbelt D, Pfeiffer D, Young L, Wood J. Risk factors for anaesthetic-related death in cats: results from the confidential enquiry into perioperative small animal fatalities (CEPSAF). British journal of anaesthesia. 2007;99(5):617-23.
8. McLellan GJ, Miller PE. Feline glaucoma—a comprehensive review. Veterinary ophthalmology. 2011;14:15-29.
9. Klein HE, Krohne SG, Moore GE, Stiles J. Postoperative complications and visual outcomes of phacoemulsification in 103 dogs (179 eyes): 2006–2008. Veterinary ophthalmology. 2011;14(2):114-20.
10. Yavuz B, Kompella UB. Ocular drug delivery. Pharmacologic therapy of ocular disease: Springer; 2016. p. 57-93.
11. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Investigative ophthalmology & visual science. 2000;41(5):961-4.
12. Sapino S, Chirio D, Peira E, Abellán Rubio E, Brunella V, Jadhav SA, et al. Ocular drug delivery: a special focus on the thermosensitive approach. Nanomaterials. 2019;9(6):884.
13. Zhao L, Chen X-J, Zhu J, Xi Y-B, Yang X, Hu L-D, et al. Lanosterol reverses protein aggregation in cataracts. Nature. 2015;523(7562):607-11.
14. Focht EF, Merriam Jr GR, Schwartz M, Velasquez J, McNeill D. A method of radiation cataract analysis and its uses in experimental fractionation studies. Radiology. 1966;87(3):465-
15. Worgul B. Cataract analysis and the assessment of radiation risk in space. Advances in Space Research. 1986;6(11):285-93.
16. Upadhyay A, Amanullah A, Mishra R, Kumar A, Mishra A. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases. Molecular neurobiology. 2018;55(2):1169-82.
17. Jani HS, Patel YR, Prajapati AK, Ranch KM. Ocular Drug Delivery Systems. Novel Drug Delivery Systems (Part 2): Bentham Science Publishers; 2024. p. 82-128.
18. Shihan MH, Novo SG, Duncan MK. Cataract surgeon viewpoints on the need for novel preventative anti-inflammatory and anti-posterior capsular opacification therapies. Current medical research and opinion. 2019;35(11):1971-81.
19. Congress MOS. Malaysian Ophthalmology Scientific Congress 2025-Abstract Book. Malaysian Journal of Ophthalmology. 2025;7(2Supp).
20. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in therapy. 2018;35(11):1763-74.
21.Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. JNCI: Journal of the National Cancer Institute. 2017;109(11):djx187.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 LOH HENG MENG, LEK QIN YING, ZHANG PENGFEI
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
